Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atrial Flutter

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    81 result(s) found for: Atrial Flutter. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2017-003836-35 Sponsor Protocol Number: 2017-001-COPAF Start Date*: 2018-08-17
    Sponsor Name:Population Health Research Institute
    Full Title: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)
    Medical condition: Perioperative atrial fibrillation / atrial flutter after thoracic surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003662 Atrial flutter PT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001905-42 Sponsor Protocol Number: LDLL600.201 Start Date*: 2014-10-23
    Sponsor Name:AOP Oprhan Pharmaceuticals AG
    Full Title: Open-label Two-arm PD and PK Study of Landiolol in Patients with Tachycardic Atrial Fibrillation or Atrial Flutter
    Medical condition: 20 Caucasian patients with tachycardic atrial fibrillation (AF) or atrial flutter (AFL)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001062-15 Sponsor Protocol Number: BAY59-7939/16320 Start Date*: 2013-06-13
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label, international, multicenter, interventional study exploring the efficacy of once-daily oral rivaroxaban (BAY 59-7939) for the treatment of left atrial/left atrial appendage thrombus i...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    16.1 10007541 - Cardiac disorders 10003662 Atrial flutter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005525-48 Sponsor Protocol Number: AK-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Diakonhjemmet hospital
    Full Title: Potassium infusion for conversion of atrial fibrillation/atrial flutter.
    Medical condition: Atrial fibrillation / atrial flutter
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001129-17 Sponsor Protocol Number: LDLL300.301 Start Date*: 2017-06-19
    Sponsor Name:AOP Orphan Pharmaceuticals GmbH
    Full Title: A multicenter, open-label study to investigate the effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED).
    Medical condition: Supraventricular tachycardia in pediatric patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    20.0 10007541 - Cardiac disorders 10074640 Junctional ectopic tachycardia PT
    20.0 10007541 - Cardiac disorders 10042604 Supraventricular tachycardia PT
    20.0 10007541 - Cardiac disorders 10003662 Atrial flutter PT
    20.0 10007541 - Cardiac disorders 10040752 Sinus tachycardia PT
    20.0 10007541 - Cardiac disorders 10003668 Atrial tachycardia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Ongoing) LT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-001124-31 Sponsor Protocol Number: VDM 02/08 Start Date*: 2008-04-11
    Sponsor Name:UZ Leuven
    Full Title: Can the use of statin reduce the incidence of atrial flutter after major non-cardiac thoracic surgery ? A randomised double-blind study.
    Medical condition: Prevention of atrial flutter after major non-cardiac thoracic surgery.
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000715-98 Sponsor Protocol Number: EFC5555 Start Date*: 2005-12-28
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A placebo-controlled, double blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with...
    Medical condition: atrial fibrillation/atrial flutter
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003658 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SE (Completed) FI (Completed) CZ (Completed) BE (Completed) NO (Completed) IT (Completed) PT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000823-40 Sponsor Protocol Number: DRI5760 Start Date*: 2005-08-01
    Sponsor Name:Sanofi-Synthelabo-Recherche
    Full Title: Double blind placebo controlled dose ranging study of the efficacy and safety of SSR149744C 300 or 600 mg for the conversion of atrial fibrillation/flutter
    Medical condition: Atrial fibrillation/flutter
    Disease: Version SOC Term Classification Code Term Level
    7.1 10003658 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004969-41 Sponsor Protocol Number: SPA-S-891/051 Start Date*: 2006-02-14
    Sponsor Name:SOCIETA PRODOTTI ANTIBIOTICI
    Full Title: A double-blind, controlled vs placebo trial to evaluate the efficacy of EPA and DHA ethyl esters, in addition to usual antiarrhythmic therapy, in the manintenance of synus rythm in patients candida...
    Medical condition: Patients with persistent atrial fibrillation candidated to electrical cardioversion.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10003658 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002210-13 Sponsor Protocol Number: STARC210421 Start Date*: 2022-01-17
    Sponsor Name:The department of cardiac, thoracic and vascular surgery - Odense University Hospital
    Full Title: Post-Operative Atrial Fibrillation after Surgical Aortic Valve Replacement and the influence of HMG-CoA reductase inhibitors
    Medical condition: Trial 2: Condition under investigation: Postoperative atrial fibrillation after surgical aortic valve replacement. In patients no prior usage of statins: 14 days prior surgery to 30days after - Ato...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003660 Atrial fibrillation and flutter LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001336-62 Sponsor Protocol Number: 2019-ASPIREAF Start Date*: 2020-04-01
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial
    Medical condition: Perioperative atrial fibrillation after noncardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10042244 Stroke LLT
    20.0 100000004866 10005103 Bleeding LLT
    20.0 100000004849 10003663 Atrial flutter/ fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) IT (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019791-73 Sponsor Protocol Number: EFC11405 Start Date*: 2010-07-22
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrill...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) HU (Completed) BE (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) DE (Completed) IT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003455-36 Sponsor Protocol Number: D3190C00005 Start Date*: 2007-12-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Multi-centre, Double-blind, Randomised, Placebo-controlled, Single-dose, Phase II Study to Assess the Effects on Atrial and Ventricular Refractoriness and Haemodynamics of an Intravenous Infusion...
    Medical condition: AZD1305 is a novel antiarrhythmic agent being developed for treatment of atrial fibrillation (AF). Potential indications include conversion of AF to sinus rhythm (SR) and maintenance of SR after c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000346-21 Sponsor Protocol Number: S219.3.118 Start Date*: 2004-11-05
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Intravenous Tedisamil Sesquifumarate in the Rapid Conversion to Normal Sinus Rhythm in Female Subjects with Recent Onset Atr...
    Medical condition: Recent Onset Atrial Fibrillation or Flutter
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001766-40 Sponsor Protocol Number: DRI5165 Start Date*: 2004-12-20
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: Placebo controlled double blind dose ranging study of the efficacy and safety of SSR149744C 50, 100, 200, or 300 mg OD, with amiodarone as calibrator for the maintenance of sinus rhythm in patients...
    Medical condition: Atrial fibrillation/flutter
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003658 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) DK (Completed) IT (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000984-81 Sponsor Protocol Number: 04-7-010 Start Date*: 2004-09-09
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER
    Medical condition: Arrhythmias are abnormal rhythms of the heart. The term arrhythmia refers to a deviation from the normal sequence of initiation and conduction of electrical impulses, which cause the heart to beat....
    Disease: Version SOC Term Classification Code Term Level
    61 10003658 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-017838-44 Sponsor Protocol Number: CJO-201 Start Date*: 2010-04-21
    Sponsor Name:Sequel Pharmaceuticals, Inc.
    Full Title: A Pilot Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Safety, Tolerability and Preliminary Efficacy Study of K201 Oral for the Prevention of Atrial Fibrillation (AF) Recurre...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003658 Atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001354-25 Sponsor Protocol Number: Start Date*: 2005-07-26
    Sponsor Name:University of Dundee
    Full Title: Use of Omega-3 poyunsaturated Fatty Acid Supplements to Maintain Sinus Rhythm in Persistent Atrial Fibrillation:a prospective and randomised study.
    Medical condition: Patients with persistent atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024552-28 Sponsor Protocol Number: 1 Start Date*: 2012-12-03
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: BRUISE CONTROL : BRidge or continUe coumadIn for device SurgEry randomized CONTROLled Trial
    Medical condition: The primary study endpoint is the risk of haematoma formation with cardiac device operation using either warfarin anticoagulation or heparin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000055-41 Sponsor Protocol Number: CV185-220 Start Date*: 2013-08-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
    Medical condition: Patients with Non-Valvular Atrial Fibrillation with at least one risk factor for stroke and indicated for oral anticoagulant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 11:31:44 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA